2,4-二溴-1-甲基-1H-咪唑 | 53857-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2,4-二溴-1-甲基-1H-咪唑
• 英文名称: 2,4-dibromo-1-methyl-1H-imidazole
• 英文别名: 2,4-dibromo-1-methylimidazole
• CAS: 53857-60-6
• 化学式: C₄H₄Br₂N₂
• 分子量: 239.897
• InChiKey: LDZBHYJUCHWPIT-UHFFFAOYSA-N

物化性质

• 熔点：
  74-76
• 沸点：
  302.3±34.0 °C(Predicted)
• 密度：
  2.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933290090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,4-Dibromo-1-methyl-1H-imidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,4-Dibromo-1-methyl-1H-imidazole
CAS number: 53857-60-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H4Br2N2
Molecular weight: 239.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二溴-1-甲基-1H-咪唑 在 caesium carbonate 、 Diphenylphosphine oxide 作用下， 以 甲苯 为溶剂， 反应 5.5h， 生成 4-溴-1-甲基-1H-咪唑
  参考文献：
  名称：

  一种通过 Pd 催化磷酸化制备包含杂环片段的非对称双（叔氧化膦）的方法

  摘要：

  通过连续引入氧化膦基团，以良好的收率合成了具有不同五元和六元杂环片段的非对称叔氧化膦，例如吡啶、2,2'-联吡啶、1,10-菲咯啉、喹啉、咪唑和噻唑通过 Pd 催化的磷酸化反应进入初始的二卤化杂环。吡啶类化合物的合成受到竞争性双偶联的阻碍，而对于五元杂环，主要困难是脱卤。通过使用过量的二卤化物（在产品纯化步骤中可以很容易地回收）、钯的合适膦配体和非极性溶剂（如甲苯）成功地抑制了这两个副过程。

  DOI：

  10.1055/s-0040-1706419
• 作为产物：
  描述：

  4,5-二溴-1-甲基-1H-咪唑 在 正丁基锂 、 溴 作用下， 生成 2,4-二溴-1-甲基-1H-咪唑
  参考文献：
  名称：

  Borai, M. El; Moustafa, A. H.; Anwar, M., Polish Journal of Chemistry, 1981, vol. 55, # 7/8, p. 1659 - 1665

  摘要：

  DOI：

文献信息

• [EN] HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS MODIFICATEURS D'HÉMOGLOBINE ET LEURS UTILISATIONS
  申请人：FRONTHERA U S PHARMACEUTICALS LLC

  公开号：WO2017218960A1

  公开（公告）日：2017-12-21

  Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.

  本文描述了化合物，包括其药用可接受的盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及使用这些化合物治疗、预防或诊断基于血液的疾病、紊乱或状况的方法。
• [EN] PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS<br/>[FR] PURINONES UTILISÉS COMME INHIBITEURS DE LA PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE 1
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2017087837A1

  公开（公告）日：2017-05-26

  The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: (I), where R1, R2, R3, R3', R4, R5, X1, X2, X3, X4, and n are described herein.

  该应用涉及对USP1的抑制剂，用于治疗癌症和其他与USP1相关的疾病和紊乱，其化学式为：(I)，其中R1、R2、R3、R3'、R4、R5、X1、X2、X3、X4和n如本文所述。
• [EN] QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS DE QUINAZOLINE EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2013050527A1

  公开（公告）日：2013-04-11

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式I化合物的治疗有效量。
• SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS
  申请人：Dahmann Georg

  公开号：US20080051578A1

  公开（公告）日：2008-02-28

  The present invention relates to compounds of general formula (I) wherein A, B, L, R 1 , R 2 , R 3a and R 3b are defined as in the specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

  本发明涉及一般式(I)的化合物，其中A、B、L、R1、R2、R3a和R3b如规范中定义，其互变异构体、对映体、非对映体、其混合物及其盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的性质。
• [EN] INHIBITORS OF CYTOMEGALOVIRUS<br/>[FR] INHIBITEURS DE CYTOMÉGALOVIRUS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014070978A1

  公开（公告）日：2014-05-08

  Compounds of Formula (I) wherein n, R1, R1A, R2, R3, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

  式（I）中的化合物，其中n，R1，R1A，R2，R3，Y和Z在此处定义，对于治疗巨细胞病毒病和/或感染是有用的。